How Did COVID-19 Impact the Antimicrobial Consumption and Bacterial Resistance Profiles in Brazil?

Natália Cassago Marcos Massarine, Gleyce Hellen de Almeida de Souza, Isadora Batista Nunes, Túlio Máximo Salomé, Marcelo Dos Santos Barbosa, Izadora Faccin, Luana Rossato, Simone Simionatto
Author Information
  1. Natália Cassago Marcos Massarine: Health Sciences Research Laboratory, Universidade Federal da Grande Dourados, Dourados 79825-070, MS, Brazil.
  2. Gleyce Hellen de Almeida de Souza: Health Sciences Research Laboratory, Universidade Federal da Grande Dourados, Dourados 79825-070, MS, Brazil.
  3. Isadora Batista Nunes: Health Sciences Research Laboratory, Universidade Federal da Grande Dourados, Dourados 79825-070, MS, Brazil.
  4. Túlio Máximo Salomé: Health Sciences Research Laboratory, Universidade Federal da Grande Dourados, Dourados 79825-070, MS, Brazil. ORCID
  5. Marcelo Dos Santos Barbosa: Health Sciences Research Laboratory, Universidade Federal da Grande Dourados, Dourados 79825-070, MS, Brazil.
  6. Izadora Faccin: Health Sciences Research Laboratory, Universidade Federal da Grande Dourados, Dourados 79825-070, MS, Brazil. ORCID
  7. Luana Rossato: Health Sciences Research Laboratory, Universidade Federal da Grande Dourados, Dourados 79825-070, MS, Brazil. ORCID
  8. Simone Simionatto: Health Sciences Research Laboratory, Universidade Federal da Grande Dourados, Dourados 79825-070, MS, Brazil. ORCID

Abstract

The indiscriminate use of antibiotics has favored the selective pressure of multidrug resistance among microorganisms. This research evaluated the pattern of antibiotic prescriptions among the Brazilian population between January 2018 and December 2021. Additionally, the study sought to analyze the incidence rates of central line-associated bloodstream infection (CLABSI) and examine the profiles of antibiotic resistance. We assessed the hospital and community antimicrobial consumption from the National Health Surveillance Agency Database and correlated it to microorganisms. The consumption of antimicrobials in the hospital environment increased by 26% in 2021, highlighting polymyxin B, which increased by 204%. In 2021, 244,266 cases of CLABSI were reported, indicating a nosocomial infection rate of 7.9%. The rate of resistance to polymyxin B was higher in (1400%) and (514%). Azithromycin emerged as the predominant antibiotic utilized within the community setting, accounting for 24% of the overall consumption. Pearson's correlation analysis revealed a significant and positive correlation (r = 0.71) between the elevated usage of azithromycin and the incidence of COVID-19. Our results indicate an increase in antimicrobial consumption during the COVID-19 pandemic and reinforce the fact that the misuse of antimicrobials may lead to an expansion in antimicrobial resistance.

Keywords

References

  1. Clin Microbiol Infect. 2021 Apr;27(4):520-531 [PMID: 33418017]
  2. Clin Microbiol Infect. 2015 Apr;21(4):344.e13-21 [PMID: 25658520]
  3. ERJ Open Res. 2021 Feb 07;8(1): [PMID: 35141318]
  4. J Antimicrob Chemother. 2021 Jul 26;76(12 Suppl 2):ii68-ii78 [PMID: 34312659]
  5. Euro Surveill. 2021 Nov;26(46): [PMID: 34794534]
  6. Trop Med Health. 2021 Jun 23;49(1):51 [PMID: 34162445]
  7. Crit Care Med. 2020 Jun;48(6):e440-e469 [PMID: 32224769]
  8. Front Pharmacol. 2022 Mar 21;13:844818 [PMID: 35387351]
  9. Am J Infect Control. 2020 Dec;48(12):1533-1536 [PMID: 33011336]
  10. Clin Infect Dis. 2021 Aug 2;73(3):e652-e660 [PMID: 33373435]
  11. Clin Microbiol Infect. 2022 Mar;28(3):426-432 [PMID: 34757115]
  12. Open Forum Infect Dis. 2021 Apr 13;8(6):ofab185 [PMID: 34183981]
  13. J Infect. 2019 Jan;78(1):8-18 [PMID: 29981773]
  14. Cochrane Database Syst Rev. 2015 Mar 08;(3):CD001954 [PMID: 25749735]
  15. Int J Antimicrob Agents. 2020 Mar;55(3):105882 [PMID: 31923570]
  16. Cien Saude Colet. 2017 Jan;22(1):221-233 [PMID: 28076545]
  17. Nat Rev Microbiol. 2020 Aug;18(8):409-410 [PMID: 32488173]
  18. Am J Infect Control. 2020 Sep;48(9):1129-1130 [PMID: 32603851]
  19. N Engl J Med. 2020 Apr 30;382(18):1708-1720 [PMID: 32109013]
  20. Lancet. 2022 Feb 12;399(10325):629-655 [PMID: 35065702]
  21. Lancet. 2020 Mar 28;395(10229):1054-1062 [PMID: 32171076]
  22. Braz J Microbiol. 2016 Dec;47 Suppl 1:31-37 [PMID: 27825605]
  23. Euro Surveill. 2018 Jul;23(30): [PMID: 30064544]
  24. J Clin Med. 2020 Aug 25;9(9): [PMID: 32854334]
  25. Lancet Reg Health Am. 2021 Dec;4:100089 [PMID: 34611650]
  26. BMJ. 2020 May 18;369:m1983 [PMID: 32423901]
  27. Medicine (Baltimore). 2015 Sep;94(38):e1605 [PMID: 26402824]
  28. Antibiotics (Basel). 2020 Nov 28;9(12): [PMID: 33260698]
  29. Int J Infect Dis. 2021 Sep;110:141-150 [PMID: 34273518]
  30. J Antimicrob Chemother. 2020 Jul 1;75(7):1681-1684 [PMID: 32433765]
  31. S D Med. 2015;Spec No:44-8 [PMID: 25985608]
  32. Clin Microbiol Infect. 2020 Dec;26(12):1622-1629 [PMID: 32711058]
  33. BMJ. 1998 Sep 5;317(7159):609-10 [PMID: 9727981]
  34. Int J Antimicrob Agents. 2021 Apr;57(4):106324 [PMID: 33746045]
  35. Environ Sci Pollut Res Int. 2020 Jun;27(17):21013-21020 [PMID: 32266618]
  36. Rev Soc Bras Med Trop. 2020 Nov 06;53:e20200248 [PMID: 33174956]
  37. Nature. 2016 Jan 21;529(7586):336-43 [PMID: 26791724]
  38. Clin Infect Dis. 2020 Dec 3;71(9):2459-2468 [PMID: 32358954]
  39. Cien Saude Colet. 2011 Jun;16(6):2963-73 [PMID: 21709993]
  40. PLoS One. 2019 Mar 21;14(3):e0214052 [PMID: 30897186]
  41. J Antimicrob Chemother. 2023 Mar 2;78(3):840-849 [PMID: 36740939]

Grants

  1. 401727/2020-3; 307946/2022-3/Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
  2. 325/2022;113/2023;76/2023/Fundação de Apoio ao Desenvolvimento do Ensino, Ciência e Tecnologia do Estado de Mato Grosso do Sul (FUNDECT)

Word Cloud

Created with Highcharts 10.0.0resistanceantimicrobialconsumptionantibiotic2021COVID-19amongmicroorganismsincidenceinfectionCLABSIhospitalcommunityantimicrobialsincreasedpolymyxinBratecorrelationindiscriminateuseantibioticsfavoredselectivepressuremultidrugresearchevaluatedpatternprescriptionsBrazilianpopulationJanuary2018DecemberAdditionallystudysoughtanalyzeratescentralline-associatedbloodstreamexamineprofilesassessedNationalHealthSurveillanceAgencyDatabasecorrelatedenvironment26%highlighting204%244266casesreportedindicatingnosocomial79%higher1400%514%Azithromycinemergedpredominantutilizedwithinsettingaccounting24%overallPearson'sanalysisrevealedsignificantpositiver=071elevatedusageazithromycinresultsindicateincreasepandemicreinforcefactmisusemayleadexpansionImpactAntimicrobialConsumptionBacterialResistanceProfilesBrazil?SARS-CoV-2healthcare-relatedinfectionsHAIs

Similar Articles

Cited By